Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance

Phio advances PH-762 with first commercial-scale cGMP batch, Phase 2b study set for Q1 2027.

What the company is saying

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is announcing the successful release of its first commercial-scale cGMP batch of PH-762 drug substance, which it frames as a critical operational and strategic milestone. The company emphasizes compliance with cGMP regulations, the approved Master Batch Record, and ICH Q7 guidelines, highlighting quality and regulatory rigor. The announcement stresses that this achievement results from a 16-month, complex, cross-functional process involving many scientists and engineers. Robert Bitterman, President and CEO, positions this milestone as mitigating key development and manufacturing risks and enabling the company to pursue upcoming clinical and regulatory milestones. The company is explicit that the validated drug substance will now move to final drug product completion for use in a planned Phase 2b clinical study, with initiation targeted for the first quarter of 2027. PH-762 is described as an INTASYL compound that silences the PD-1 gene, with prior Phase 1b evaluation in cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The tone is confident and forward-looking, with an emphasis on supply chain readiness and the potential for PH-762 as a non-surgical skin cancer treatment.

What the data suggests

The release confirms the successful manufacture of the first commercial-scale cGMP batch of PH-762, validated by a Certificate of Analysis and Certificate of Compliance. Manufacturing followed cGMP regulations, the Master Batch Record, and ICH Q7 guidelines, indicating regulatory compliance for clinical-grade material. The operational process took approximately 16 months and involved significant scientific and engineering resources. The company states that this batch will be used for final drug product completion, supporting a planned Phase 2b clinical study expected to begin in Q1 2027. The only clinical data referenced is the prior Phase 1b trial (NCT# 06014086), but no efficacy or safety results are disclosed. Claims of supply chain readiness, risk mitigation, and commercial potential are asserted but not supported by quantitative evidence or detailed downstream plans. No financial figures, funding status, or cash runway information are provided, and the announcement does not address capital adequacy for the next clinical phase.

Analysis

The announcement highlights a genuine operational milestone—the successful release of the first commercial-scale cGMP batch of PH-762 drug substance, which is a concrete achievement. However, much of the language inflates the significance of this step by projecting future benefits (clinical advancement, supply chain readiness, commercialization potential) that are not yet realized. The next major milestone, initiation of the Phase 2b clinical study, is not expected until Q1 2027, over a year away, indicating a long-term execution horizon. The announcement references a complex, resource-intensive process (16 months, numerous scientists and engineers), suggesting significant capital and operational investment, but does not disclose any financials or funding status. Several claims about risk mitigation, supply chain readiness, and positioning for commercialization are forward-looking and lack supporting quantitative evidence. The overall tone is optimistic and promotional, but the actual realized progress is limited to manufacturing a batch for future clinical use.

Risk flags

• ●Execution risk is high as the company must complete final drug product manufacturing and initiate the Phase 2b clinical study within a tight timeline, with no disclosed contingency plans or buffer for delays.
• ●Financial risk is present since the announcement does not disclose cash position, funding secured for Phase 2b, or capital adequacy, leaving uncertainty about the company's ability to finance upcoming clinical and manufacturing activities.
• ●Clinical and regulatory risk is material, as the efficacy and safety of PH-762 remain unproven in later-stage trials, and the company has not disclosed outcome data from the Phase 1b trial or details of regulatory feedback.
• ●Commercialization risk persists because claims of supply chain readiness and commercial potential are not backed by evidence of downstream manufacturing, distribution agreements, or market access plans.

Bottom line

Phio Pharmaceuticals has achieved a concrete operational milestone with the first commercial-scale cGMP batch of PH-762, demonstrating manufacturing and regulatory compliance. The company is now positioned to complete drug product manufacturing and aims to initiate a Phase 2b clinical study in Q1 2027, but no efficacy, safety, or financial data are disclosed. While the announcement highlights supply chain readiness and risk mitigation, these claims are not substantiated with quantitative evidence or details about downstream capabilities. The absence of funding or cash runway disclosure raises questions about the company's ability to finance the next clinical phase. Investors should focus on the completion of drug product manufacturing, the actual start of the Phase 2b trial, and future disclosures of clinical outcomes and financial status. The most important takeaway is that while operational progress is real, the path to clinical and commercial value remains long and uncertain.

Announcement summary

(NASDAQ: PHIO) Phio Pharmaceuticals Corp. announced the successful release of its first commercial-scale cGMP batch of PH-762 drug substance (active pharmaceutical ingredient), marking a critical operational and strategic milestone as the company advances PH-762 to the next stage of clinical development. The batch was manufactured in accordance with established specifications and quality requirements, as confirmed by the Certificate of Analysis and Certificate of Compliance. Manufacturing was conducted in compliance with current Good Manufacturing Practice (cGMP) regulations, the approved Master Batch Record, and applicable ICH Q7 guidelines. The validated drug substance will now proceed through the final steps of drug product completion for use in Phio's planned Phase 2b clinical study. The drug product is expected to be initiated in the first quarter of 2027. This milestone demonstrates the company's supply chain readiness and supports the next steps in its clinical development and potential commercialization strategy for PH-762. Robert Bitterman, President and CEO of Phio Pharmaceuticals, stated that this achievement culminates a complex coordination and cross-functional execution process started approximately 16 months ago among numerous highly skilled scientists and engineers. He described the milestone as a meaningful advancement in the PH-762 program, mitigating key development and manufacturing risks, and positioning the company to execute on important upcoming clinical and regulatory milestones. Phio's lead clinical development program is PH-762, an INTASYL compound that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. PH-762 is described as a potential non-surgical treatment for skin cancers.

Disagree with this article?